Brelovitug (BJT-778) is a humanized IgG1 neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg). Brelovitug has significant antiviral activity, and neutralizes and removes HBV and HDV as well as depleting HBsAg-containing subviral particles. Brelovitug can be used for HDV and HBV infections, chronic hepatitis delta (CHD) and chronic hepatitis B (CHB) research[1][2].
Molecular Weight:
(143.954 kDa)
Purity:
99
CAS Number:
[3033337-14-0]
Target:
HBV
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted